2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1450 Phip mutations increase clonal fitness and reveal therapeutic vulnerabilities in acute myeloid leukemia

Bailee Nicole Kain, PhD, Duc Tran, PhD2, Kevin Watanabe-Smith, PhD3, Deedra Nicolet, MS4, Sierra Bennett-Weltz, BS5, Yueh-Chiang Hu, PhD6, Lorenz Oelschlaeger, MD7, Jeffrey Tyner, PhD8, Kelly Bolton, MD, PhD9, Christopher J Walker, Ph.D.10, Ann-Kathrin Eisfeld, MD11, Nathan Salomonis, PhD12, H. Leighton Grimes, PhD13
1 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
2 Washington University, Saint Louis, Missouri, United States
3 Oregon Health and Science University School of Medicine, Portland, Oregon, United States
4 Alliance Statistics and Data Management Center, Columbus, Ohio, United States, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, Ohio, United States
5 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
6 Cincinnati Children's Hospital, Cincinnati, United States
7 Cincinnati Children's Hospital, Cincinnati, Ohio, United States
8 Oregon Health and Science University School of Medicine, Portland, Oregon, United States, Oregon Health and Science University School of Medicine, Portland, Oregon, United States
9 Washington University, Saint Louis, Missouri, United States
10 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
11 Alliance Statistics and Data Management Center, Columbus, Ohio, United States, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, Ohio, United States, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 Cincinnati Children's Hospital, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, United States
13 Cincinnati Children's Hospital, Cincinnati, Ohio, United States

Pleckstrin homology domain interacting protein (PHIP) encodes a chromatin-reading E3 ubiquitin ligase substrate receptor and is recurrently mutated in clonal hematopoiesis (CH), myelodysplastic neoplasms (MDS), and acute myeloid leukemia (AML). While previously reported knock in models (PhipY1316X/+) demonstrated leukemogenic activity of PHIP, the extent to which distinct PHIP mutations alter preleukemic fitness, cooperate across additional AML genotypes, and create targetable dependencies was unknown.

To gain insights into the possible impact of PHIP CH and MDS on AML progression, we centrally analyzed the UK Biobank, All of Us, and MDS IWG datasets for PHIP variants. Notably, individuals with PHIP-mutant CH had significantly increased odds of developing AML (p=0.0187). In MDS, PHIP-mutant patients had Revised International Prognostic Scoring System (IPSS-R) scores and overall survival rates similar to patients with intermediate risk mutations. This clinical data supports that PHIP mutations mark CH/MDS and predict AML progression risk.

To test causality, we generated knock-in mice carrying orthologs of observed human mutations PhipS272P/+ or PhipY1316X/+. CD117+ bone marrow cells from both knock-in models showed increased clonogenicity 7 days post plating. In primary and secondary 20-week competitive transplants, both knock-in alleles caused increased donor chimerism and accumulation of hematopoietic stem cells. Interestingly, each knock-in model exhibited differential skewing of the multipotent progenitor (MPP) pool post transplantation, with expansion of MPP1/MPP2 and MPP3/MPP4 populations in PhipS272P/+ and PhipY1316X/+ mice, respectively. Thus, distinct Phip mutations impose context dependent hematopoiesis yet confer dominant HSPC fitness.

Next, we evaluated the relationship between Phip mutations and common AML genotypes found to co-occur with PHIP mutations in patients. We found Phip+/- and PhipS272P/+ collaborate with Flt3ITD/+ to generate lethal AMLs. PhipY1316X/+ also accelerated disease in Flt3ITD/Npm1c mice. Because PHIP mutations are enriched in inv(16) AML, we introduced CBF-MYH11 into PhipS272P/+ and PhipY1316X/+ models carrying Flt3ITD and observed an approximately two-fold acceleration of disease progression. PhipY1316X/+ also collaborated with CBF-MYH11 NrasG12D/+ to significantly decrease survival, a mutation combination found in PHIPY1316X/+ human AML.

Recently it was found that PHIP loss of function allows the nucleosome remodeling and deacetylase (NuRD)  complex to invade SWI/SNF target genes. We observed significant cross-species downregulation of genes related to chromatin remodeling/binding in single cell captures of PhipY1316X/+ mutated AML GEMMs and a PHIPY1316X/+ patient specimen. To test this newly implicated chromatin dependency, we treated PHIP-knockout THP-1 cells with BPK-25, a NuRD degrader. PHIP-knockout cells had a lower BPK-25 IC50 and significantly greater Annexin V positivity at 48 hours, identifying a PHIP-dependent NuRD vulnerability. Thus, our cross species scRNAseq analysis and functional evaluation of NuRD vulnerability reveal conserved downregulation of genes critical for epigenetic remodeling.

Finally, we derived a PHIP-pathway-activity transcriptome signature and explored its association with patient outcome. Although established using Alliance AML patients, the signature retained prognostic value in 3 independent AML cohorts (AMLCG, TCGA, and BEAT AML). Although PHIP was included in the prognostic signature, PHIP transcript abundance alone did not predict survival. Using BEAT AML v1.0 drug-response data, we compared PHIP-signature-high and PHIP-signature-low specimens within the European LeukemiaNet (ELN) adverse-risk group. Signature-high samples were more sensitive than signature-low samples to Indisulam, Entrectinib, and Birinapant. PHIP-knockout THP-1 cells independently validated all 3 predictions, with significantly greater apoptosis than controls 48 hours after treatment. Therefore, this PHIP signature robustly predicts poor AML survival and exposes targetable liabilities in PHIP related pathways.

Together, our data establish PHIP mutations as drivers of preleukemic clonal fitness, broaden the AML genotypes in which PHIP accelerates leukemia, and identify PHIP pathway activity as a prognostic and drug-response biomarker. The results nominate NuRD degradation, Indisulam, Entrectinib, and Birinapant for further evaluation in PHIP-mutant or PHIP-signature-high AML.

Bailee Nicole Kain, PhD: No relevant conflicts of interest to declare.